Pro Medicus (ASX:PME) - CEO Dr Sam Hupert
CEO Dr Sam Hupert
Source: Pro Medicus
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Pro Medicus (PME)’s wholly owned subsidiary has signed a $40 million contract with Novant Health
  • Visage Imaging penned a seven-year contract, which will see the company’s Visage 7 Enterprise Imaging Platform and Visage 7 Workflow module implemented throughout Novant Health
  • Planning for the rollout is set to start immediately, with launch dates targeted for the second half of the financial year, deployed on the Microsoft Azure cloud
  • Pro Medicus is down 1.1 per cent, trading at $54.01 at 12:20 pm AEST

Pro Medicus (PME)’s wholly owned subsidiary has signed a $40 million contract with Novant Health.

Visage Imaging penned the seven-year contract which will see the company’s Visage 7 Enterprise Imaging Platform and Visage 7 Workflow module implemented throughout Novant Health, providing a unified diagnostic imaging platform across the network.  

Planning ahead of the rollout is set to start immediately, with launch dates targeted for the second half of the financial year.

Pro Medicus CEO Sam Hupert explained the implementation would be fully deployed on the Microsoft Azure cloud.

“Novant Health is our seventh major North American contract in less than 18 months and our equal largest deal to date, underpinning the strong momentum we continue to build in the market,” Dr Hupert said.

Novant Health also joins an increasing number of clients to opt for a fully cloud-based solution.

“Our pipeline remains strong. Deals like this confirm our view that Visage 7, with its proven cloud native technology and modular design, provides us with a significant strategic advantage that enables us to address opportunities across a growing segment of the market both in North America and other regions,” Dr Hupert said.

Pro Medicus was down 1.1 per cent, trading at $54.01 at 12:20 pm AEST.

PME by the numbers
More From The Market Online

This stock provides Oz’s only HIV self-test kit – and it’s bullish on the budget

Atomo Diagnostics is the only company in Australia that provides TGA-approved HIV self-test kits. It says…

Recce Pharma heading closer to full efficacy data for flagship R327

Recce Pharma has announced the latest cohort of patients in the company's Phase I/II UTI trial…
The Market Online Video

Breaking barriers in cancer treatment: Race Oncology pioneers a new era with bisantrene

Race Oncology (ASX:RAC) has announced positive results in killing cancer cells in combination with the drug…

Optiscan agreement with Mayo Clinic aims to expedite robotic surgery

Optiscan Imaging is parterning with Mayo Clinic to develop a digital confocal laser endomicroscopic imaging system